InnoCare Pharma Limited INCPF
Set alert
At close · Oct 30
- YTD
- -21.95%
- 1 year
- -50.92%
- Open
- 1.60
- Prev close
- 1.60
- Mkt cap
- 2.83B
- Vol
- 200
- Avg vol
- 42
- EPS
- 0.08
- P/E
- 20.00
More statistics
- Low
- 1.60
- High
- 1.60
- Earnings
- Aug 25, 2026
News
1 month ago reuters.com
China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion
Chinese drugmaker InnoCare Pharma said on Thursday it entered into a research collaboration and license agreement with Eli Lilly that could be worth up to about $3.35 billion.
2 months ago seekingalpha.com
InnoCare Pharma Limited (INCPF) Q2 2026 Earnings Call Transcript
InnoCare Pharma Limited (INCPF) Q2 2026 Earnings Call Transcript
3 months ago reuters.com
China's Innocare's psoriasis drug meets main goal in late-stage trial
China-based Innocare Pharma said on Monday the Phase III trial of fadeucravacitinib, an experimental treatment for moderate-to-severe plaque psoriasis, has met its primary endpoint.
3 months ago globenewswire.com
InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China
BEIJING, July 05, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today…
5 months ago globenewswire.com
Phase IIb Study Results of InnoCare's Orelabrutinib in Patients with SLE Presented at 2026 EULAR
BEIJING, June 05, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today…
5 months ago globenewswire.com
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
BEIJING, June 02, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today…
5 months ago globenewswire.com
InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China
BEIJING, May 28, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today…
5 months ago globenewswire.com
InnoCare Announces Approval of Orelabrutinib in Australia
BEIJING, May 27, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that…
5 months ago globenewswire.com
2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released
BEIJING, May 22, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today…
5 months ago globenewswire.com
InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ICP-054 (ZB021) in healthy volunteers - Phase 1 SAD and MAD data expected by year-end 2026
5 months ago globenewswire.com
InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren's Syndrome in China
BEIJING, May 07, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today…
5 months ago globenewswire.com
InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China
BEIJING, May 06, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today…
6 months ago globenewswire.com
InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE
Orelabrutinib is the first BTKi to demonstrate significant efficacy in a Phase II clinical trial for SLE, which affects around 8 million people worldwide.
6 months ago globenewswire.com
InnoCare Releases 2026 Q1 Results: Strong Revenue Growth and Sustained Profitability
BEIJING, April 23, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428) today announced its results and business highlights for the first quarter of 2026 as of 31 March 2026. Over the…
7 months ago seekingalpha.com
InnoCare Pharma Limited (INCPF) Q4 2025 Earnings Call Transcript
InnoCare Pharma Limited (INCPF) Q4 2025 Earnings Call Transcript
7 months ago globenewswire.com
InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit
BEIJING, March 25, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the annual…
7 months ago globenewswire.com
InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China
BEIJING, March 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced…
8 months ago globenewswire.com
InnoCare Announces Key Developments of Critical Clinical Studies
BEIJING, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today key clinical…
10 months ago globenewswire.com
InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
BEIJING, Dec. 17, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today…
10 months ago globenewswire.com
Over 20 Studies of InnoCare's Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
BEIJING, Dec. 09, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today…